Rare blood clots more likely after COVID-19 infection than from vaccine, report finds
An analysis led by Brown University neurologist Dr. Karen L. Furie in partnership with the American Heart Association/American Stroke Association, put the post-vaccine risk of CVST in perspective.
PROVIDENCE, R.I. [Brown University] The rare blood clot disorder reported by some Johnson & Johnson coronavirus vaccine recipients is also a risk of COVID-19 infection, according to a new report by the American Heart Association/American Stroke Association Stroke Council Leadership.
Dr. Karen L. Furie, chair of the Department of Neurology at Brown’s Warren Alpert Medical School, served as lead author of the report, which synthesized existing data from more than 81 million patients and found that risk of developing CVST blood clots is eight to 10 times higher following a COVID-19 infection as compared to the risk associated with receipt of a COVID-19 vaccine.
The rare blood clot condition that affected a small number of people who got the Johnson & Johnson COVID-19 vaccine is eight to 10 times more likely to occur from a COVID-19 infection than from the vaccine, according to a special report from the American Heart Association/American Stroke Association Stroke Council Leadership.
Here & Now s Robin Young speaks to the author of that special report,
Dr. Karen Furie, who is the neurologist in chief at Rhode Island Hospital and the chair of neurology at the Warren Alpert Medical School of Brown University.
This segment aired on May 5, 2021.